Rituximab treatment for spondyloarthritis. A nationwide series: Data from the AIR registry of the French Society of Rheumatology

Journal of Rheumatology

Volumn 39, Issue 12, 2012, Pages 2327-2331

  Wendling, Daniel ^a   Dougados, Maxime ^b   Berenbaum, Francis ^c   Brocq, Olivier ^d   Schaeverbeke, Thierry ^e   Mazieres, Bernard ^f   Marcelli, Christian ^g   LeParc, Jean Marie ^h   Bertin, Philippe ⁱ   Robin, Michèle ^j   Sibilia, Jean ^k   Lafforgue, Pierre ^l   Prati, Clément ^a   Combe, Bernard ^m   Gottenberg, Jacques Eric ^k  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^e HÔPITAL PELLEGRIN   (France)

^f CHU RANGUEIL   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h HÔPITAL AMBROISE PARÉ   (France)

ⁱ LIMOGES UNIVERSITY HOSPITAL   (France)

^j General Hospital   (France)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^m MONTPELLIER UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Air registry; Ankylosing spondylitis; Psoriatic arthritis; Rituximab spondyloarthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALLOCHRYSINE; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; INFLIXIMAB; LEFLUNOMIDE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEMALE; HEART FAILURE; HUMAN; INFECTION; INFUSION RELATED REACTION; KNEE PROSTHESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDIASTINAL ADENOMEGALY; MEDIASTINUM DISEASE; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; NEOPLASM; PRIORITY JOURNAL; PROSTHESIS INFECTION; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SHOULDER ARTHROPLASTY; SPONDYLARTHRITIS; TREATMENT RESPONSE; UVEITIS; VEIN THROMBOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; C-REACTIVE PROTEIN; DRUG SUBSTITUTION; FEMALE; FRANCE; HEALTH STATUS; HUMANS; JOINTS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870318190     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120201     Document Type: Article

References (18)

1. Lin Q, Gu JR, Li TW, Zhang FC, Lin ZM, Liao ZT, et al. Value of the peripheral blood B-cells subsets in patients with ankylosing spondylitis. Chin Med J (Engl) 2009;122:1784-9.
2. Voswinkel J, Weisgerber K, Pfreundschuh M, Gause A. B lymphocyte involvement in ankylosing spondylitis: the heavy chain variable segment gene repertoire of B lymphocytes from germinal center-like foci in the synovial membrane indicates antigen selection. Arthritis Res 2001;3:189-95. (Pubitemid 32303436)
3. Wendling D, Didier JM, Seilles E. Serum secretory immunoglobulins in ankylosing spondylitis. Clin Rheumatol 1996;15:590-3. (Pubitemid 26405575)
4. Appel H, Loddenkemper C, Grozdanovic Z, Ebhardt H, Dreimann M, Hempfing A, et al. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006;8:R143.
5. Rodríguez-Escalera C, Fernández-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology 2008;47:1732-3.
6. Wendling D, Augé B, Streit G, Toussirot E, Mathieu S. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008;75:510-1.
7. Cohen JD. Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008;67:1647-8.
8. Huang Y, Cheng F, Zhang X, Tang J. Marked reduction of sacroiliac joint inflammation on magnetic resonance imaging in a patient with ankylosing spondylitis after rituximab treatment. J Rheumatol 2011;38:2083-4.
9. Nocturne G, Dougados M, Constantin A, Richez C, Sellam J, Simon A, et al. Rituximab in the spondyloarthropathies: Data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis 2010;69:471-2.
10. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial. Arthritis Rheum 2010;62:1290-7.
11. Mease P, Kavanaugh A, Genovese M, Ritchlin C, Rosengren S, Quistberg A, et al. Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions [abstract]. Arthritis Rheum 2010;62 Suppl:S818.
12. Mielke F, Schneider-Obermeyer J, Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008;67:1056-7. (Pubitemid 351956683)
13. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007;56:2715-8. (Pubitemid 47237290)
14. Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011;11:35-9.
15. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, et al CRI. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10.
16. Baeten D, Kruithof E, Breban M, Tak PP. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum 2008;58:730-3. (Pubitemid 351364870)
17. Wendling D, Prati C, Goupille P, Mulleman D. Optimizing TNFα antagonist therapy in patients with spondyloarthritis: Why and how? Joint Bone Spine 2011;78:225-7.
18. Wendling D, Prati C. Biologic agents for treating ankylosing spondylitis: Beyond TNFα antagonists. Joint Bone Spine 2011;78:542-4.